Research directory
Peptide compounds, organized by evidence and regulatory status
A curated reference of peptide research compounds drawn from public biomedical databases. Each entry lists mechanism summaries, regulatory status, evidence quality, safety flags, and links to peer-reviewed literature — never dosing, protocols, or sourcing.
CJC-1295 (no DAC)
Modified GRF(1-29)
Short-acting GHRH(1-29) analog without the DAC linker. Studied as a research-only compound.
CJC-1295 with DAC
CJC-1295 (DAC:GRF)
GHRH analog conjugated to a drug-affinity-complex (DAC) extending half-life. Clinical development by ConjuChem was halted after a Phase II trial reported...
GHRP-2
Growth Hormone Releasing Peptide-2
Synthetic ghrelin mimetic studied as a diagnostic tool for growth-hormone deficiency in some markets.
GHRP-6
Growth Hormone Secretagogues reference entry
Ghrelin receptor agonist studied as a research compound for GH release; produces appetite stimulation in early trials.
Hexarelin
Growth Hormone Secretagogues reference entry
Synthetic hexapeptide ghrelin mimetic studied for transient GH release and cardiovascular effects in animal models.
Ipamorelin
Growth Hormone Secretagogues reference entry
Selective ghrelin receptor agonist that has been studied for transient growth-hormone release without significant cortisol or prolactin effects in early trials.
MK-677
Ibutamoren
Non-peptide oral ghrelin receptor agonist studied in trials for sarcopenia and frailty. Development was not pursued to approval.
Sermorelin
GHRH(1-29)
Synthetic analog of the first 29 amino acids of GHRH. Previously FDA-approved as Geref for pediatric growth hormone deficiency; commercial product...
Tesamorelin
Growth Hormone Secretagogues reference entry
GHRH analog with a stabilized N-terminus. FDA-approved as Egrifta specifically for the reduction of excess abdominal fat in HIV-infected patients with...